I am much more negative on TMDX. I think it's a low quality business that won't hit volume or margin targets due to competitive pressures that will emerge in the next few years. My reasons below:
1) Undifferentiated business model
The NOP model actually lowers stickiness and barriers to entry. Medical devices are typically "sticky" because hospital staff need to be trained, with multi-year contracts reinforcing product adoption. The NOP model of bundling service and product - streamlining the process to a simple phone call - eliminates switching costs and commoditizes the business model.
This would be fine if the technology was somehow differentiated, but it's not. This isn't complex tech at all. And there isn't evidence to show that that TMDX is superior to OrganOx, Liver Transport, or VitaSmart in liver viability ex-vivo. OrganOx got transport approval in September of last year. The CEO responded to this clear competitive threat by saying OrganOx can't compete in transport because their device "can't fit on a plane" (paraphrasing) Not kidding - google the device right now and see if you agree with this take.
I don't believe owning a fleet of planes is a differentiator. If the ROI is there, OrganOx will undertake the capex project, or just lease the planes. The whitespace is white enough for multiple players each with fleets.
Once TMDX starts getting competed against directly, the choice for customers quickly becomes “who gives me acceptable outcomes at the lowest cost with decent service,” especially given OrganOx is roughly one‑third the cost.
2) Unrealistic Volume Target
The 10,000‑organ target is very unrealistic. It leans heavily on DCD (donation after criculatory death) growth that would require uncontrolled DCD to work and be adopted at scale, which recent U.S. data and European experience don’t really support yet. It's a very novel idea. Beyond DCD, the Company also points to an opportunity in kidney transplantation, a lower-ASP market already dominated by LifePort, which has utilized perfusion technology for decades. This is also not to mention the negative tailwinds associated with kidney transplant volumes long-term (GLP-1s lowering incidence of diabetes - the primary reason for kidney transplantation)
3) NRP is a threat
Management likes to play up NMP (normothermic machine perfusion - the tech TMDX uses) vs cold storage. This is a strawman. The real argument is NMP vs NRP (normothermic regional perfusion).
NRP can cover multiple organs per run (and thus is usually cheaper on a per-organ basis). It also shows DCD outcomes comparable to DBD—often at a lower per‑organ cost.
While NRP is used at both the hospital and organ procurement organization (OPO) levels, TransMedics is structurally limited in its ability to compete with OPO-driven NRP solutions, as the company sells exclusively to hospitals.
Thank you for the detailed bear case — this is exactly the kind of rigorous debate that helps investors make better decisions. Let me share some fundamental data points that complement your analysis.
On the NOP model and barriers to entry:
You raise a fair point about switching costs in traditional medical devices. However, the data tells a different story for TMDX specifically. Market share grew from 13.8% to 20.9% in just one year. Revenue increased 32.2% YoY in Q3 2025. If the NOP model truly commoditized the business, we'd expect share erosion — not acceleration.
Regarding OrganOx: leasing planes is one thing, but replicating an integrated logistics network of 21+ aircraft with optimized routing, trained flight crews, and perfusion specialists is a multi-year operational build. The moat isn't the planes — it's the system around them. And while OrganOx received transport approval in September, TMDX has been scaling transport operations for years. That operational head start compounds over time.
On the 10,000-organ volume target:
The target is ambitious — no question. But let's look at the execution trajectory: Q3 EPS of $0.66 vs consensus of $0.37 — a 78% beat. EPS growth of 100% YoY. Gross margin expanding from 57.4% to 60.3%. Net margin nearly doubling from 10.1% to 16.2%.
These aren't projections — they're reported results showing a company that is scaling efficiently. Is 10,000 a stretch? Possibly. But with over 103,000 patients on U.S. transplant waiting lists and global transplant volumes growing at 8.9% CAGR, the addressable market supports aggressive growth assumptions.
On the DCD point specifically: you're right that uncontrolled DCD adoption at scale remains unproven. But TMDX doesn't need DCD to hit meaningful growth — their current trajectory on DBD organs alone is already delivering triple-digit earnings growth.
On NRP as a competitive threat:
This is your strongest argument, and one we monitor closely. However, NMP and NRP serve different segments of the transplant workflow. NRP operates at the procurement level — it's a hospital/OPO solution. NMP operates at the transport and assessment level — it's a logistics solution. They can coexist, and in many cases are complementary rather than substitutive.
Additionally, NRP adoption in the U.S. faces significant regulatory and ethical hurdles that aren't resolved quickly. While Europe has moved faster, the U.S. regulatory environment is fundamentally more cautious on this front.
Where I agree with you:
The valuation premium is real — TMDX trades at 53x earnings vs 30.7x for the industry.
That's a 73% premium that demands continued execution. EPS growth is expected to decelerate from 100% to 25.1%, and with 21.8% short interest, the market clearly sees risk.
The PEG ratio tells an interesting story though: PEG1 of 0.53 suggests current growth isn't fully priced in, while PEG2 of 1.69 shows the market is pricing in the deceleration.
This is a stock where timing and monitoring matter enormously.
Bottom line: The bear case you present is legitimate and every TMDX investor should understand these risks. From a fundamental standpoint, the current financial trajectory supports the bull case — but it requires near-flawless execution to justify the premium.
That's exactly why continuous fundamental monitoring matters more than a one-time buy/sell decision.
One stock, two perspectives. Now imagine having this level of clarity across 50+ stocks every single day. imgeld.com
Not going to respond to every point here but a few things
1) it’s too early for market share to erode you’re right. This is more of a structural case against the company. It will be the leader in this niche for at least 3-5 years.
2) uDCD is actually a contributor to their 10k target if you examine investor decks. Completely unfounded. FYI Wall Street brokers don’t even view 10k as viable, some model at most 8.5k (Raymond James).
In cDCD NRP is a huge threat to liver (the main segment here). The version of NRP which harvests the liver (A-NRP) faces no ethical hurdles. It is only the version that pumps blood into the heart and harvest the heart that does (TA-NRP).
Clinical outcomes for NRP are comparable to traditional methods, with strong evidence supporting its efficacy. In liver transplants specifically, NRP in donation after circulatory death (DCD) cases results in ischemic cholangiopathy rates on par with donation after brain death (DBD), overcoming a key historical barrier to DCD liver utilization
Additionally, while NRP is used at both the hospital and organ procurement organization (OPO) levels, TransMedics is structurally limited in its ability to compete with OPO-driven NRP solutions, as the company sells exclusively to hospitals.
On the catalyst front, I don’t see anything on the horizon that could really rerate this thing like it did in May. It’s OUS and Kidney news (savvy investors know these aren’t real/attractive growth opportunities)
I am much more negative on TMDX. I think it's a low quality business that won't hit volume or margin targets due to competitive pressures that will emerge in the next few years. My reasons below:
1) Undifferentiated business model
The NOP model actually lowers stickiness and barriers to entry. Medical devices are typically "sticky" because hospital staff need to be trained, with multi-year contracts reinforcing product adoption. The NOP model of bundling service and product - streamlining the process to a simple phone call - eliminates switching costs and commoditizes the business model.
This would be fine if the technology was somehow differentiated, but it's not. This isn't complex tech at all. And there isn't evidence to show that that TMDX is superior to OrganOx, Liver Transport, or VitaSmart in liver viability ex-vivo. OrganOx got transport approval in September of last year. The CEO responded to this clear competitive threat by saying OrganOx can't compete in transport because their device "can't fit on a plane" (paraphrasing) Not kidding - google the device right now and see if you agree with this take.
I don't believe owning a fleet of planes is a differentiator. If the ROI is there, OrganOx will undertake the capex project, or just lease the planes. The whitespace is white enough for multiple players each with fleets.
Once TMDX starts getting competed against directly, the choice for customers quickly becomes “who gives me acceptable outcomes at the lowest cost with decent service,” especially given OrganOx is roughly one‑third the cost.
2) Unrealistic Volume Target
The 10,000‑organ target is very unrealistic. It leans heavily on DCD (donation after criculatory death) growth that would require uncontrolled DCD to work and be adopted at scale, which recent U.S. data and European experience don’t really support yet. It's a very novel idea. Beyond DCD, the Company also points to an opportunity in kidney transplantation, a lower-ASP market already dominated by LifePort, which has utilized perfusion technology for decades. This is also not to mention the negative tailwinds associated with kidney transplant volumes long-term (GLP-1s lowering incidence of diabetes - the primary reason for kidney transplantation)
3) NRP is a threat
Management likes to play up NMP (normothermic machine perfusion - the tech TMDX uses) vs cold storage. This is a strawman. The real argument is NMP vs NRP (normothermic regional perfusion).
NRP can cover multiple organs per run (and thus is usually cheaper on a per-organ basis). It also shows DCD outcomes comparable to DBD—often at a lower per‑organ cost.
While NRP is used at both the hospital and organ procurement organization (OPO) levels, TransMedics is structurally limited in its ability to compete with OPO-driven NRP solutions, as the company sells exclusively to hospitals.
Thank you for the detailed bear case — this is exactly the kind of rigorous debate that helps investors make better decisions. Let me share some fundamental data points that complement your analysis.
On the NOP model and barriers to entry:
You raise a fair point about switching costs in traditional medical devices. However, the data tells a different story for TMDX specifically. Market share grew from 13.8% to 20.9% in just one year. Revenue increased 32.2% YoY in Q3 2025. If the NOP model truly commoditized the business, we'd expect share erosion — not acceleration.
Regarding OrganOx: leasing planes is one thing, but replicating an integrated logistics network of 21+ aircraft with optimized routing, trained flight crews, and perfusion specialists is a multi-year operational build. The moat isn't the planes — it's the system around them. And while OrganOx received transport approval in September, TMDX has been scaling transport operations for years. That operational head start compounds over time.
On the 10,000-organ volume target:
The target is ambitious — no question. But let's look at the execution trajectory: Q3 EPS of $0.66 vs consensus of $0.37 — a 78% beat. EPS growth of 100% YoY. Gross margin expanding from 57.4% to 60.3%. Net margin nearly doubling from 10.1% to 16.2%.
These aren't projections — they're reported results showing a company that is scaling efficiently. Is 10,000 a stretch? Possibly. But with over 103,000 patients on U.S. transplant waiting lists and global transplant volumes growing at 8.9% CAGR, the addressable market supports aggressive growth assumptions.
On the DCD point specifically: you're right that uncontrolled DCD adoption at scale remains unproven. But TMDX doesn't need DCD to hit meaningful growth — their current trajectory on DBD organs alone is already delivering triple-digit earnings growth.
On NRP as a competitive threat:
This is your strongest argument, and one we monitor closely. However, NMP and NRP serve different segments of the transplant workflow. NRP operates at the procurement level — it's a hospital/OPO solution. NMP operates at the transport and assessment level — it's a logistics solution. They can coexist, and in many cases are complementary rather than substitutive.
Additionally, NRP adoption in the U.S. faces significant regulatory and ethical hurdles that aren't resolved quickly. While Europe has moved faster, the U.S. regulatory environment is fundamentally more cautious on this front.
Where I agree with you:
The valuation premium is real — TMDX trades at 53x earnings vs 30.7x for the industry.
That's a 73% premium that demands continued execution. EPS growth is expected to decelerate from 100% to 25.1%, and with 21.8% short interest, the market clearly sees risk.
The PEG ratio tells an interesting story though: PEG1 of 0.53 suggests current growth isn't fully priced in, while PEG2 of 1.69 shows the market is pricing in the deceleration.
This is a stock where timing and monitoring matter enormously.
Bottom line: The bear case you present is legitimate and every TMDX investor should understand these risks. From a fundamental standpoint, the current financial trajectory supports the bull case — but it requires near-flawless execution to justify the premium.
That's exactly why continuous fundamental monitoring matters more than a one-time buy/sell decision.
One stock, two perspectives. Now imagine having this level of clarity across 50+ stocks every single day. imgeld.com
Not going to respond to every point here but a few things
1) it’s too early for market share to erode you’re right. This is more of a structural case against the company. It will be the leader in this niche for at least 3-5 years.
2) uDCD is actually a contributor to their 10k target if you examine investor decks. Completely unfounded. FYI Wall Street brokers don’t even view 10k as viable, some model at most 8.5k (Raymond James).
In cDCD NRP is a huge threat to liver (the main segment here). The version of NRP which harvests the liver (A-NRP) faces no ethical hurdles. It is only the version that pumps blood into the heart and harvest the heart that does (TA-NRP).
Clinical outcomes for NRP are comparable to traditional methods, with strong evidence supporting its efficacy. In liver transplants specifically, NRP in donation after circulatory death (DCD) cases results in ischemic cholangiopathy rates on par with donation after brain death (DBD), overcoming a key historical barrier to DCD liver utilization
Additionally, while NRP is used at both the hospital and organ procurement organization (OPO) levels, TransMedics is structurally limited in its ability to compete with OPO-driven NRP solutions, as the company sells exclusively to hospitals.
On the catalyst front, I don’t see anything on the horizon that could really rerate this thing like it did in May. It’s OUS and Kidney news (savvy investors know these aren’t real/attractive growth opportunities)
Good exchange — and you've sharpened my thinking on A-NRP, which I'll be watching closely.
Appreciate the debate.